Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval
Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...
Drug
Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy
Ignis Therapeutics announced that cenobamate tablets received marketing approval from China’s National Medical Products Administration...
Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness
Ignis Therapeutics announced that Solriamfetol Hydrochloride Tablets received approval from China’s National Medical Products Administration...
Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia
Abbisko Cayman Limited (HKG: 2256) announced preliminary results from the dose escalation phase of the...
Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase 1/2 data for LBL-034 in relapsed/refractory multiple...
Junshi Biosciences roconkibart psoriasis NMPA Acceptance
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announces that the National Medical Products...
CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...
Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive
Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative...
Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval
Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...
Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted
Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products...
Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal
Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:...
Juventas CAR-T LBCL Launch Marks Second Indication
Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...
BMS Breyanzi MZL FDA Approval First CAR-T
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...
Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...
Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...
TransThera Tinengotinib Cholangiocarcinoma Priority Review China
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...
Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma
Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...
CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...
Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications
Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...